Results 31 to 40 of about 588,459 (256)

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation

Medicine in Drug Discovery, 2022
Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao, Rui Li, Xing Pei, Meihong Chai, Lu Sun, Yuanyu Huang, Jiancheng Wang, Stefan Barth, Fei Yu, Huining He   +9 more
doaj   +1 more source

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Nature Communications, 2020
Antibody-drug conjugates targeting high expression receptors can suffer from poor tumour penetration. Here, the authors use unconjugated antibody to improve the penetration of an antibody-dye conjugate in a clinical study, supporting further clinical ...
Guolan Lu, Naoki Nishio, Nynke S. van den Berg, Brock A. Martin, Shayan Fakurnejad, Stan van Keulen, Alexander D. Colevas, Greg M. Thurber, Eben L. Rosenthal   +8 more
doaj   +1 more source

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Cancer Medicine, 2021
Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy.
Wen-Qian Li, Han-Fei Guo, Lingyu Li, Yong-fei Zhang, J. Cui   +4 more
semanticscholar   +1 more source

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Ophthalmology and Therapy, 2020
Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl ...
Asim V. Farooq, S. Degli Esposti, R. Popat, P. Thulasi, S. Lonial, A. Nooka, A. Jakubowiak, D. Sborov, B. Zaugg, A. Badros, B. Jeng, N. Callander, J. Opalinska, January Baron, T. Piontek, J. Byrne, I. Gupta, K. Colby   +17 more
semanticscholar   +1 more source

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

Cancer Research, 2021
These findings show that targeting AXL-positive tumor fractions with an antibody–drug conjugate enhances anti-tumor immunity in several humanized tumor models of melanoma and lung cancer.
J. Boshuizen, N. Pencheva, O. Krijgsman, Daniela D’Empaire Altimari, P. G. Castro, Beaunelle de Bruijn, M. Ligtenberg, Elke Gresnigt-van den Heuvel, David W. Vredevoogd, Ji-Ying Song, Nils L. Visser, Georgi Apriamashvili, M. Janmaat, T. Plantinga, P. Franken, M. Houtkamp, A. Lingnau, M. Jure-Kunkel, D. Peeper   +18 more
semanticscholar   +1 more source

A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]

, 2019
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella, Maso, Katia, Monia Montagner, Isabella, Pasut, Gianfranco, Rosato, Antonio, Schiavon, Oddone   +5 more
core   +1 more source

Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum

Molecules, 2023
Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu, Yajun Sun, Xiaojie Deng, Lili Shi, Wenyi Chen, Wenjing Fang, Junliang Wu, Xiaotian Fan, Xiaoqiang Chen, Jianhua Sun, Gang Qin, Likun Gong, Qiuping Qin   +12 more
doaj   +1 more source

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches

Pharmaceuticals, 2021
In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain, Armin Grimm, Wenjie Sheng, Chaoyu Zhang, Marwah Al-Rawe, Karen Bräutigam, Mobarak Abu Mraheil, Felix Zeppernick, Ivo Meinhold-Heerlein   +8 more
doaj   +1 more source